Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Nabilone

FDA-approved product (capsule, oral), marketed as Cesamet.

Registered studies
35
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Nabilone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Nausea
  • Nausea and vomiting
  • Post operative nausea and vomiting

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antiemetics
FDA pharmacologic class
Cannabinoid FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli29.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis37.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

35registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Nabilone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Nabilone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Multiple Sclerosis

    NCT00381264 · start 2006-09

    Registered record
    Registry ID
    NCT00381264
    Conditions
    Multiple Sclerosis
    Interventions
    Cesamet™ (nabilone)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-09
    Completion
    2007-10
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis
    InterventionCesamet™ (nabilone)
    PhasePhase 4
    Registry statusCompleted

  • A Phase IV Trial of Cesamet™ Given With Standard Antiemetic Therapy for Chemotherapy-induced Nausea and Vomiting

    NCT00418678 · start 2006-08

    Registered record
    Registry ID
    NCT00418678
    Conditions
    Nausea and Vomiting
    Interventions
    Cesamet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2006-08
    Completion
    2007-12
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNausea and Vomiting
    InterventionCesamet
    PhasePhase 4
    Registry statusTerminated

  • A Trial Assessing the Effect of Nabilone on Pain and Quality of Life in Patients With Fibromyalgia

    NCT00272207 · start 2006-04

    Registered record
    Registry ID
    NCT00272207
    Conditions
    Fibromyalgia
    Interventions
    Nabilone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-04
    Completion
    2007-03
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFibromyalgia
    InterventionNabilone
    PhasePhase 2
    Registry statusCompleted

  • Nabilone Versus Amitriptyline in Improving Quality of Sleep in Patients With Fibromyalgia

    NCT00381199 · start 2006-04

    Registered record
    Registry ID
    NCT00381199
    Conditions
    Fibromyalgia; Sleep Initiation and Maintenance Disorders
    Interventions
    Amitriptyline Hydrochloride; Nabilone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-04
    Completion
    2007-03
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFibromyalgia; Sleep Initiation and Maintenance Disorders
    InterventionAmitriptyline Hydrochloride; Nabilone
    PhaseNot applicable
    Registry statusCompleted

  • Use of the Cannabinoid Nabilone for the Promotion of Sleep in Chronic, Non-Malignant Pain Patients

    NCT00384410 · start 2005-12

    Registered record
    Registry ID
    NCT00384410
    Conditions
    Pain; Insomnia
    Interventions
    Nabilone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2005-12
    Completion
    Not recorded
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPain; Insomnia
    InterventionNabilone
    PhasePhase 2
    Registry statusUnknown